Mable, a San Francisco, CA-based genomics-powered telehealth clinic focused specifically on migraine care, raised $3.2M in seed funding.
The round was led by Initialized Capital with support from First In Ventures, Arkitekt Ventures and Inaki Berenguer. The round also includes pre-seed funding from Y Combinator and Illumina, Inc.
The company intends to use the funds to expand operations and its business reach.
Led by Roman Rothaermel, Co-founder & CEO, Mable provides a patent-pending genomics-powered telehealth clinic focused specifically on migraine care. It uses an individual’s DNA to create preventive and acute plans customized to that person’s unique needs. With the right plan in place, Mable then delivers appropriate medication straight to their door and offers them ongoing expert care in the comfort of their home.